SBNO2

Across TCGA pan-cancer cohorts, SBNO2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SBNO2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SBNO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SBNO2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where SBNO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.331	0.835	.019	10	view →
UCEC	OS	Median	II,III,IV	1.000	0.705	.039	4	view →
LUAD	OS	Median	All	1.000	0.705	.021	2	view →
LSCC	DFS	Median	II,III,IV	0.650	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SBNO2–PDAC (DFS)

Open the PDAC breakdown →